TY - JOUR
T1 - Severe cutaneous adverse drug reactions
T2 - Who should treat, Where and how?: Facts and controversies
AU - Wolf, Ronni
AU - Davidovici, Batya
PY - 2010/5
Y1 - 2010/5
N2 - Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are uncommon but extremely serious and often life-threatening mucocutaneous reactions characterized by extensive epithelial sloughing and systemic symptoms. There is no effective evidence-based treatment for severe cutaneous adverse reactions (SCAR) to drugs and no consensus on how to treat these patients. This contribution presents some of the controversies concerning the treatment of SCAR patients, including where and by whom, as well as the issue of the value of treatment with corticosteroids and intravenous immunoglobulin. Investigators agree that more studies are needed and that there are insufficient data to draw definite conclusions. The spectrum of disagreement is wide and the debate is ongoing. At the end, the important question is should we wait with our decisions until all these controversies are settled and we have more or full evidence. This question, as well as all others, is open for debate, evidently a "toxic" debate on toxic epidermal necrolysis.
AB - Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are uncommon but extremely serious and often life-threatening mucocutaneous reactions characterized by extensive epithelial sloughing and systemic symptoms. There is no effective evidence-based treatment for severe cutaneous adverse reactions (SCAR) to drugs and no consensus on how to treat these patients. This contribution presents some of the controversies concerning the treatment of SCAR patients, including where and by whom, as well as the issue of the value of treatment with corticosteroids and intravenous immunoglobulin. Investigators agree that more studies are needed and that there are insufficient data to draw definite conclusions. The spectrum of disagreement is wide and the debate is ongoing. At the end, the important question is should we wait with our decisions until all these controversies are settled and we have more or full evidence. This question, as well as all others, is open for debate, evidently a "toxic" debate on toxic epidermal necrolysis.
UR - http://www.scopus.com/inward/record.url?scp=77953592420&partnerID=8YFLogxK
U2 - 10.1016/j.clindermatol.2009.06.020
DO - 10.1016/j.clindermatol.2009.06.020
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 20541690
AN - SCOPUS:77953592420
SN - 0738-081X
VL - 28
SP - 344
EP - 348
JO - Clinics in Dermatology
JF - Clinics in Dermatology
IS - 3
ER -